For research use only
| Cat No. | ABC-X0015C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
This cell line models the FGFR2-BICC1 (E565G) fusion mutation to support drug screening and functional analysis in FGFR2-driven tumor studies.
The FGFR2 (E565G) BICC1 BAF3 Cell Line is engineered by introducing the human FGFR2-BICC1 fusion gene containing an E565G activating mutation into BAF3 cells via lentiviral vectors. The E565G mutation enhances FGFR2 kinase activity and oncogenic transformation.
Target
FGFR2-BICC1 fusions are recurrent in intrahepatic cholangiocarcinoma. The E565G mutation within the kinase domain enhances ligand-independent activation and promotes oncogenic signaling. This model facilitates study of FGFR2 fusion-driven carcinogenesis and drug responses. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0015C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell line supports high-throughput screening of FGFR inhibitors, biomarker discovery, and validation of therapeutic agents targeting FGFR2 alterations in liver and bile duct cancers. It is suitable for mechanistic pathway analysis and resistance profiling.